Oracea Called Best Nonantibiotic for Rosacea

Pending its approval, this drug will be added to the list of therapies that don’t contribute to resistance.

BY BRUCE JANCIN
Denver Bureau

KOLOA, HAWAII — With marketing approval pending, the nonantibiotic, nonproprietary formulation of doxycycline for treatment of rosacea widely anticipated by the end of this month, this new once-daily oral agent is likely to be viewed as the best therapeutic option for patients with papulopustular forms of the disease, Dr. Hilary E. Baldwin said at the annual Hawaii dermatology seminar sponsored by the Skin Disease Education Foundation.

It has long been recognized that conventional antibiotics—particularly those in the tetracycline class—are highly effective in rosacea, even though it is now clear that the disease isn’t actually caused by bacteria. However, long-term use of antimicrobials to treat a chronic disease such as rosacea, which may last for decades, is increasingly seen as irresponsible because it contributes to the rise of antibiotic-resistant, highly pathogenic bacteria.

“This is not a minor problem. It’s not something that people are making up. It’s a truly global impact problem. And by treating a nonbacterial disease with antibiotics, we’re adding to the problem,” stressed Dr. Baldwin of the State University of New York, Brooklyn.

Fortunately, physicians have access to a range of nonantibiotic alternatives in treating rosacea. The best of them could be Oracea: its once-daily formulation of doxycycline is far cheaper than lasers, devoid of the teratogenicity concerns posed by oral and topical retinoids, and far more effective than β-blockers and other anti-flushing medications, she said.

Here are the nonantibiotic alternatives:

- **Oracea.** Food and Drug Administration approval is anticipated for this agent as a 40-mg controlled release drug indicated for treatment of rosacea. Its big selling point, in addition to efficacy—is that this dose lies below the drug’s threshold of antibiotic activity. Hence, there are no concerns regarding the emergence of bacterial resistance.

  In two double-blind, placebo-controlled, phase III trials, 537 rosacea patients were randomized to Oracea or placebo once daily for 16 weeks. Patients on Oracea experienced mean reductions in inflammatory lesion count of 61% and 46%, compared with 29% and 20%, respectively, for placebo.

  The drug’s mechanisms of benefit in rosacea are believed to involve inhibition of neutrophil-derived serum matrix metalloproteinases, downregulation of inflammatory cytokines, inhibition of nitric oxide activity as well as that of other active oxygen species, and suppression of the arachidonic acid pathway.

  In addition, Oracea inhibits collagenase activity, which is increased in rosacea and is thought to be a cause of the dystrophic dermal connective tissue that’s a disease hallmark, the dermatologist continued. 

- **Topical retinoids.** These are highly effective for rosacea but have never really caught on, partly because clinical improvement isn’t seen until after 2-3 months. Most patients don’t want to wait that long.

  “You can certainly add a topical retinoid at the initiation of therapy along with something that gives a bit more bang for the buck,” he said in an interview.

  In his presentation, he suggested that antibiotic resistance was a concern because rosacea is a chronic disease for which patients are often treated for long periods. All tetracyclines have anti-inflammatory activity, he said, but doxycycline is the only one for which investigators have separated anti-inflammatory from antibiotic dosing.

  Anti-inflammatory–dose doxycycline is a 40-mg, controlled-release doxycycline monohydrate capsule that is administered once a day, said Dr. Del Rosso. “The advantage of once-daily dosing is obviously better patient compliance,” he added.

  All told, 537 patients at 28 sites were enrolled in the two randomized, double-blind, placebo-controlled studies. The investigator said that patients in both trials achieved significant improvements in inflammatory lesion counts and in Investigator’s Global Assessment of Improvement scores with anti-inflammatory-dose doxycycline.

  In the two studies, patients receiving anti-inflammatory-dose doxycycline experienced a 61% and 46% mean reduction in inflammatory lesions, compared to 29% and 20%, respectively, in those receiving placebo. “In most of our hands none of these has worked very well,” she said. Complete control of flushing using prazosin, for example, seems to require dosing at 20-40 mg b.i.d. or t.i.d., and side effects are considerable at those levels.

- **Lasers and light-based therapy.** These excel where pharmaceutical therapy is weakest—rosacea involving severe erythema and telangiectasias. In addition, the CO2 and other ablative lasers are highly useful for removal of rhinophyma and prevention of recurrences.

  Vascular lasers make a great deal of sense for erythematous/telangiectatic forms of rosacea because they cause vascular destruction without collateral tissue damage, Dr. Baldwin noted.

  Photodynamic therapy with either a polychromatic or monochromatic light source along with a photosensitizing agent preferentially targets sebaceous glands but treats papulopustular forms of rosacea as well—and offers the side benefit of improved skin quality.

  Ethridium:YAG lasers and nonablative lasers are believed to work in rosacea by inducing proliferation of fibroblasts and endothelial cells, Dr. Baldwin said. She is a consultant to CollaGenex Pharmaceuticals Inc., which is developing Oracea.

  The SDEF and this news organization are wholly owned subsidiaries of Elsevier.

Anti-Inflammatory Doxycycline Clears Rosacea Lesions

BY JANE SALODOF MACNEIL
Southwest Bureau

KAPALUA, HAWAII — A formulation of doxycycline that is anti-inflammatory but does not predispose patients to development of antibiotic resistance. That is significant, he said in an interview.

- **Oracea.** Food and Drug Administration approval is anticipated for this agent as a 40-mg controlled release drug indicated for treatment of rosacea. Its big selling point—in addition to efficacy—is that this dose lies below the drug’s threshold of antibiotic activity. Hence, there are no concerns regarding the emergence of bacterial resistance.

  In two double-blind, placebo-controlled, phase III trials, 537 rosacea patients were randomized to Oracea or placebo once daily for 16 weeks. Patients on Oracea experienced mean reductions in inflammatory lesion count of 61% and 46%, compared with 29% and 20%, respectively, for placebo.

  The drug’s mechanisms of benefit in rosacea are believed to involve inhibition of neutrophil-derived serum matrix metalloproteinases, downregulation of inflammatory cytokines, inhibition of nitric oxide activity as well as that of other active oxygen species, and suppression of the arachidonic acid pathway.

  In addition, Oracea inhibits collagenase activity, which is increased in rosacea and is thought to be a cause of the dystrophic dermal connective tissue that’s a disease hallmark, the dermatologist continued. 

- **Topical retinoids.** These are highly effective for rosacea but have never really caught on, partly because clinical improvement isn’t seen until after 2-3 months. Most patients don’t want to wait that long.

  “You can certainly add a topical retinoid at the initiation of therapy along with something that gives a bit more bang for the buck,” he said in an interview.

  In his presentation, he suggested that antibiotic resistance was a concern because rosacea is a chronic disease for which patients are often treated for long periods. All tetracyclines have anti-inflammatory activity, he said, but doxycycline is the only one for which investigators have separated anti-inflammatory from antibiotic dosing.

  Anti-inflammatory–dose doxycycline is a 40-mg, controlled-release doxycycline monohydrate capsule that is administered once a day, said Dr. Del Rosso. “The advantage of once-daily dosing is obviously better patient compliance,” he added.

  All told, 537 patients at 28 sites were enrolled in the two randomized, double-blind, placebo-controlled studies. The investigator said that patients in both trials achieved significant improvements in inflammatory lesion counts and in Investigator’s Global Assessment of Improvement scores with anti-inflammatory-dose doxycycline.

  In the two studies, patients receiving anti-inflammatory-dose doxycycline experienced a 61% and 46% mean reduction in inflammatory lesions, compared to 29% and 20%, respectively, in those receiving placebo. “In most of our hands none of these has worked very well,” she said. Complete control of flushing using prazosin, for example, seems to require dosing at 20-40 mg b.i.d. or t.i.d., and side effects are considerable at those levels.

- **Lasers and light-based therapy.** These excel where pharmaceutical therapy is weakest—rosacea involving severe erythema and telangiectasias. In addition, the CO2 and other ablative lasers are highly useful for removal of rhinophyma and prevention of recurrences.

  Vascular lasers make a great deal of sense for erythematous/telangiectatic forms of rosacea because they cause vascular destruction without collateral tissue damage, Dr. Baldwin noted.

  Photodynamic therapy with either a polychromatic or monochromatic light source along with a photosensitizing agent preferentially targets sebaceous glands but treats papulopustular forms of rosacea as well—and offers the side benefit of improved skin quality.

  Ethridium:YAG lasers and nonablative lasers are believed to work in rosacea by inducing proliferation of fibroblasts and endothelial cells, Dr. Baldwin said. She is a consultant to CollaGenex Pharmaceuticals Inc., which is developing Oracea.

  The SDEF and this news organization are wholly owned subsidiaries of Elsevier.